Document is current
Any future updates will be listed below
-
Authors
Juhel, Brooke C.
Brunelle, Cheryl L.
Bernstein, Madison C.
Smith, Louisa H.
Jung, Amanda W.
Ababneh, Hazim S.
Hausman, Elizabeth K.
Bucci, Loryn K.
Bernstein, Tess
Naoum, George E.
Taghian, Alphonse G. https://orcid.org/0000-0003-2211-9355
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct048727384 at ClinicalTrials.govDocuments that mention this clinical trial
Side effects of COVID-19 vaccinations in patients treated for breast cancer
https://doi.org/10.1007/s10238-023-01050-z
-
Funding
Funding for this research was provided by:
National Cancer Institute (P50CA08393)
Adele McKinnon Research Fund for Breast Cancer-Related Lymphedema
Heinz Family Foundation
Olayan-Xefos Family Fund for Breast Cancer Research
- License Information
-
More Information
Article History
Received: 21 December 2022
Accepted: 17 March 2023
First Online: 8 April 2023
Declarations
:
: Alphonse G. Taghian has been loaned equipment from ImpediMed for use in an investigator-initiated clinical trial. Alphonse G. Taghian is on the Scientific Advisory Board of Puretech Health (not paid) and is a previous consultant for VisionRT. Both involvements are unrelated to this study. Cheryl L. Brunelle is on the Scientific Advisory Board of Puretech Health. The remaining authors have no conflict of interest.
: The Massachusetts General Hospital Institutional Review Board approved protocols 2021P000528 (COVID-19 vaccine survey) and 2021P003414 (secondary use protocol to analyze the vaccine survey in conjunction with breast cancer-related demographic and treatment factors). Consent was obtained electronically from participants prior to beginning the survey. The study was performed in accordance with the Declaration of Helsinki.
: Not applicable.
Free to read: This content has been made available to all.
